Richard P. Baum – författare

Presented for the first time in popular form is the fascinating true story of the search for the phantom planet Vulcan. As with legends of "the lost continent of Atlantis," scientists and dreamers alike have sought to prove that Vulcan is more than just a myth. Historians of astronomy Richard Baum and William Sheehan have combed the continents, digging through dusty letters and journals, to unravel this mysterious and captivating tale. The planet first assumed a shadowy reality against a backdrop of war and revolution early in the nineteenth century. Le Verrier, the autocratic Director of the Paris Observatory, had unveiled a problem with the motion of the planet Mercury. The indications were of a planet closer to the sun than Mercury. Incredibly, the prediction was immediately fulfilled by an obscure French country doctor using no more than a homemade telescope. The planet, named for the Roman god of fire, was no sooner discovered than it was lost. Still it reappeared often enough to tantalize even skeptics into considering its shadowy existence possible.This fast-paced tale follows the exploits of Le Verrier, and later of his followers, in a pursuit of his unbridled obsessions: to extend the universality of Newton's Laws, to prove Vulcan's existence, and to secure his place in history as one of the greatest astronomers of his time. Stranger than fiction, the story reaches an exciting climax in the final showdown in the unlikeliest of places: America's Wild West. Like gunslingers at high noon, determined astronomers of the opposing camps brave Indians and the elements in their attempt to prove once and for all whether the planet exists. They congregate with some of the most illustrious names of their time for the final test: a grand eclipse of the sun.

Nuclear Medicine has greatly contributed to the diagnosis and treament of neuroendocrine neoplasms. This issue of PET Clinics will focus not only on the diagnosis and treatment of neuroendocrine tumors, but also theranostics. Topics include SPECT and other PET tracers, F-DOPA, Ga-DOTA-peptides, Yttrium- and Lutetium-based therapy, and the role of FDG PET. It also covers key information of theranostics.

This issue of PET Clinics focuses on Prostate Cancer Imaging and Therapy, and is edited by Drs. Cristina Nanni and Richard P. Baum. Articles will include: Clinicians Need for Imaging of Prostate Cancer; Imaging of Prostate Cancer using 11C-Choline; Imaging of Prostate Cancer using FACBC; Imaging of Prostate Cancer using Ga-Bombesin; Imaging of Prostate Cancer using 18F-Choline; Imaging of Prostate Cancer using Cu-64 Prostate-specific membrane antigen; From bench to bed: New Gastrin releasing peptide receptor-directed radioligands and their use in prostate cancer; Imaging of Prostate Cancer using Ga-68 Prostate-specific membrane antigen; Imaging of Prostate Cancer using F-18 Prostate-specific membrane antigen; Imaging of Prostate Cancer using uPAR-PET; PET/CT for radiation therapy planning of Prostate Cancer; and more!

The recent revolution in molecular biology offers exciting new opportunities for targeted radionuclide therapy.

This book is based on contributions presented at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, which examined recent developments in theranostics – the emerging field of molecular targeting of vectors that can be used for both diagnosis and therapy, when modified accordingly.

This book is based on contributions presented at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, which examined recent developments in theranostics – the emerging field of molecular targeting of vectors that can be used for both diagnosis and therapy, when modified accordingly. The focus of this book is on the rapidly developing research into and clinical applications of gallium-68 and other generator-produced PET radionuclides in the personalized diagnosis and treatment of neuroendocrine tumors and other diseases. In addition, new PET radiopharmaceuticals are considered, and the latest ideas and concepts, presented. Theranostics embodies both molecular and personalized medicine. It is at the cutting edge of medicine, and the contents of this volume will be of interest to chemists, physicians, and investigators dealing with generators, PET radiochemistry, molecular imaging, and radionuclide therapy.

The recent revolution in molecular biology offers exciting new opportunities for targeted radionuclide therapy. This up-to-date, comprehensive book, written by world-renowned experts, discusses the basic principles of radionuclide therapy, explores in detail the available treatments, explains the regulatory requirements, and examines likely future developments. The full range of clinical applications is considered, including thyroid cancer, hematological malignancies, brain tumors, liver cancer, bone and joint disease, and neuroendocrine tumors. The combination of theoretical background and practical information will provide the reader with all the knowledge required to administer radionuclide therapy safely and effectively in the individual patient. Careful attention is also paid to the role of the therapeutic nuclear physician in coordinating a diverse multidisciplinary team, which is central to the safe provision of treatment.

It was at Frankfurt/Mainin 1899 that Paul Ehrlich first expounded his famous "site-chain theory" -which described the basic immunological principal of antibody-antigen interactio- on the occasion of the opening of the Institute for Experimental Therapeutics (which was later named after him). Nearly 100 years have passed since, and in retrospect it can be said that the "Ehrlich Era" (first steps in immunology "Magic Bullet" concept) and the "Behring Era" (detection of antibodies and serum therapy) formed the essential basis in the development of immunology. Niels K. Jerne, the former director of the Paul Ehrlich Institute in Frankfurt/Main received, together with Georges Kohler and Cesar Milstein, the Nobel Prize in Medicine 1984. These late successors of Ehrlich and Behring first described the hybridoma technology (in 1975) which enabled one of the most important and revolutionary technological innovations in the field of immunology -the production of monoclonal antibodies. It happens that, the time of the publication of this book, just a decade has passed since the first use of radiolabelled monoclonal antibodies in man (by the Lausanne Group). Over these 10 years a tremendous progress has taken place in the field of immunoscintigraphy:A large panel of highly specific monoclonal antibodies against tumour-associated antigens as well as normal cell compounds have been developed. Enormous progress has been made in the field of radiolabelling -from iodine-131 to technetium-99mor even positron-emittingradionuclides, e. g. iodine-124.